Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Dicerna Pharmaceuticals Inc (DRNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2022 SC 13G/A BALYASNY ASSET MANAGEMENT LLC reports a 0% stake in Dicerna Pharmaceuticals Inc.
01/10/2022 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
01/03/2022 EFFECT Form EFFECT - Notice of Effectiveness:
01/03/2022 EFFECT Form EFFECT - Notice of Effectiveness:
01/03/2022 EFFECT Form EFFECT - Notice of Effectiveness:
01/03/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/28/2021 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
12/28/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
12/28/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
12/28/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
12/28/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/28/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/28/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/28/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
12/28/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Second Amended and Restated Certificate of Incorporation",
"Second Amended and Restated By-Laws",
"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition LEXINGTON, Mass.—— Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. , announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021, which represent approximately 82.6..."
12/27/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/27/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/15/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/08/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/08/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/03/2021 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/24/2021 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
11/24/2021 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
11/18/2021 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
11/18/2021 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
11/18/2021 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
11/18/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Dicerna Pharmaceuticals, Inc., Novo Nordisk A/S, and NNUS New Research, Inc.",
"Novo Nordisk to Acquire Dicerna"
11/09/2021 10-Q Quarterly Report for the period ended September 30, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy